CL2007001913A1 - Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias. - Google Patents
Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias.Info
- Publication number
- CL2007001913A1 CL2007001913A1 CL2007001913A CL2007001913A CL2007001913A1 CL 2007001913 A1 CL2007001913 A1 CL 2007001913A1 CL 2007001913 A CL2007001913 A CL 2007001913A CL 2007001913 A CL2007001913 A CL 2007001913A CL 2007001913 A1 CL2007001913 A1 CL 2007001913A1
- Authority
- CL
- Chile
- Prior art keywords
- desloratadine
- loratadine
- sucralose
- povidone
- sorbitol
- Prior art date
Links
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 title abstract 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 title abstract 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 title abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 title abstract 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004376 Sucralose Substances 0.000 title abstract 2
- 229960001271 desloratadine Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 229960003088 loratadine Drugs 0.000 title abstract 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 title abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 title abstract 2
- 229940069328 povidone Drugs 0.000 title abstract 2
- 210000002345 respiratory system Anatomy 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000001509 sodium citrate Substances 0.000 title abstract 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 title abstract 2
- 239000000600 sorbitol Substances 0.000 title abstract 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 title abstract 2
- 235000019408 sucralose Nutrition 0.000 title abstract 2
- 239000006188 syrup Substances 0.000 title abstract 2
- 235000020357 syrup Nutrition 0.000 title abstract 2
- 201000004624 Dermatitis Diseases 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 208000026935 allergic disease Diseases 0.000 title 1
- 230000007815 allergy Effects 0.000 title 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 title 1
- 235000010234 sodium benzoate Nutrition 0.000 title 1
- 239000004299 sodium benzoate Substances 0.000 title 1
- 235000011083 sodium citrates Nutrition 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Formulación de jarabe antihistamínico que comprende loratadina, desloratadina o una sal de ellas o una combinación de dos o más de las mismas, propilenglicol, sorbitol, citrato de sodio, ácido cítrico, povidona, sucralosa; y uso para tratar y/o prevenir afecciones alérgicas e inflamatorias de la piel o las vías respiratorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81731206P | 2006-06-29 | 2006-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007001913A1 true CL2007001913A1 (es) | 2008-01-11 |
Family
ID=38739452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2007001913A CL2007001913A1 (es) | 2006-06-29 | 2007-06-28 | Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080262017A1 (es) |
| EP (1) | EP2037921A2 (es) |
| JP (1) | JP2009542665A (es) |
| KR (1) | KR20090024282A (es) |
| CN (1) | CN101505750A (es) |
| AR (1) | AR061668A1 (es) |
| AU (1) | AU2007269835A1 (es) |
| BR (1) | BRPI0713933A2 (es) |
| CA (1) | CA2656087A1 (es) |
| CL (1) | CL2007001913A1 (es) |
| CO (1) | CO6230988A2 (es) |
| MX (1) | MX2009000121A (es) |
| NO (1) | NO20090458L (es) |
| PE (1) | PE20080994A1 (es) |
| SG (1) | SG173333A1 (es) |
| TW (1) | TW200808374A (es) |
| WO (1) | WO2008005267A2 (es) |
| ZA (1) | ZA200900168B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101548959B (zh) * | 2008-04-03 | 2012-11-21 | 万特制药(海南)有限公司 | 一种含有地氯雷他定的包衣片剂及其制备方法 |
| WO2011146030A2 (en) * | 2010-05-18 | 2011-11-24 | Mahmut Bilgic | Effervescent antihistamine formulations |
| ES2753981T3 (es) | 2010-10-21 | 2020-04-15 | Rtu Pharmaceuticals Llc | Formulaciones de ketorolaco listas para uso |
| WO2013062497A1 (en) * | 2011-10-13 | 2013-05-02 | Mahmut Bilgic | Liquid pharmaceutical formulations |
| BR102012030828A2 (pt) | 2012-12-03 | 2014-09-16 | Ems Sa | Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso |
| CN104434789B (zh) * | 2014-12-27 | 2017-04-26 | 昆明振华制药厂有限公司 | 一种枸橼酸喷托维林糖浆的制备方法 |
| KR102242382B1 (ko) * | 2020-02-28 | 2021-04-20 | 삼익제약주식회사 | 용해성, 안정성 및 쓴맛이 개선된 로라타딘 함유 시럽 조성물 |
| CN113081958B (zh) * | 2021-05-01 | 2022-05-03 | 安徽新世纪药业有限公司 | 一种地氯雷他定口服溶液及其制备方法 |
| CN114788809B (zh) * | 2022-01-25 | 2023-04-14 | 江苏广承药业有限公司 | 一种氯雷他定液体制剂 |
| CN114767677B (zh) * | 2022-05-06 | 2023-11-07 | 成都倍特药业股份有限公司 | 一种氯雷他定组合物及其制备方法 |
| CN115475141A (zh) * | 2022-10-14 | 2022-12-16 | 漳州片仔癀药业股份有限公司 | 一种地氯雷他定口服溶液及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763449A (en) * | 1996-08-07 | 1998-06-09 | Ascent Pediatrics, Inc. | Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
| US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| WO2001089527A2 (en) * | 2000-05-24 | 2001-11-29 | Schering Corporation | Pharmaceutical composition comprising loratadine and a nasal decongestant |
| US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| US20040101563A1 (en) * | 2002-07-18 | 2004-05-27 | Kundu Subhas C. | Storage stable antihistaminic syrup formulations |
| JP3881640B2 (ja) * | 2003-08-08 | 2007-02-14 | 塩野義製薬株式会社 | ロラタジンを含むドライシロップ剤 |
| US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
| WO2005076829A2 (en) * | 2004-02-05 | 2005-08-25 | Taro Pharmaceuticals U.S.A., Inc. | Stable loratadine spill resistant formulation |
-
2007
- 2007-06-27 WO PCT/US2007/014957 patent/WO2008005267A2/en not_active Ceased
- 2007-06-27 MX MX2009000121A patent/MX2009000121A/es unknown
- 2007-06-27 AU AU2007269835A patent/AU2007269835A1/en not_active Abandoned
- 2007-06-27 AR ARP070102860A patent/AR061668A1/es not_active Application Discontinuation
- 2007-06-27 CN CNA2007800314793A patent/CN101505750A/zh active Pending
- 2007-06-27 EP EP07796520A patent/EP2037921A2/en not_active Withdrawn
- 2007-06-27 CA CA002656087A patent/CA2656087A1/en not_active Abandoned
- 2007-06-27 BR BRPI0713933-0A patent/BRPI0713933A2/pt not_active IP Right Cessation
- 2007-06-27 JP JP2009518256A patent/JP2009542665A/ja not_active Withdrawn
- 2007-06-27 SG SG2011048220A patent/SG173333A1/en unknown
- 2007-06-27 KR KR1020097001410A patent/KR20090024282A/ko not_active Abandoned
- 2007-06-27 PE PE2007000832A patent/PE20080994A1/es not_active Application Discontinuation
- 2007-06-27 US US11/769,351 patent/US20080262017A1/en not_active Abandoned
- 2007-06-28 CL CL2007001913A patent/CL2007001913A1/es unknown
- 2007-06-28 TW TW096123549A patent/TW200808374A/zh unknown
-
2008
- 2008-12-24 CO CO08136727A patent/CO6230988A2/es not_active Application Discontinuation
-
2009
- 2009-01-08 ZA ZA200900168A patent/ZA200900168B/xx unknown
- 2009-01-28 NO NO20090458A patent/NO20090458L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008005267A2 (en) | 2008-01-10 |
| AR061668A1 (es) | 2008-09-10 |
| ZA200900168B (en) | 2010-06-30 |
| JP2009542665A (ja) | 2009-12-03 |
| CO6230988A2 (es) | 2010-12-20 |
| AU2007269835A1 (en) | 2008-01-10 |
| EP2037921A2 (en) | 2009-03-25 |
| TW200808374A (en) | 2008-02-16 |
| CN101505750A (zh) | 2009-08-12 |
| WO2008005267A3 (en) | 2008-07-10 |
| MX2009000121A (es) | 2009-01-26 |
| PE20080994A1 (es) | 2008-08-06 |
| CA2656087A1 (en) | 2008-01-10 |
| BRPI0713933A2 (pt) | 2012-12-18 |
| KR20090024282A (ko) | 2009-03-06 |
| SG173333A1 (en) | 2011-08-29 |
| NO20090458L (no) | 2009-01-28 |
| US20080262017A1 (en) | 2008-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007001913A1 (es) | Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias. | |
| EP1973595A4 (en) | ACTIVE CANNULA FOR BIOMASS AND SURGICAL INTERVENTIONS | |
| EP2016939A4 (en) | TRANSDERMAL RESORBABLE PREPARATION WITH A MEANS OF DAMAGE | |
| DK2121614T3 (da) | Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer | |
| CY1110133T1 (el) | Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ | |
| PL2042041T3 (pl) | Zastosowanie kwasu benzoesowego i tymolu, eugenolu i piperyny w żywieniu zwierząt | |
| PT3111927T (pt) | Composições para administração respiratória de agentes ativos e métodos e sistemas associados | |
| BR112014000775A2 (pt) | curativo de ferimento e método de tratamento | |
| EP2083774A4 (en) | THERAPEUTIC INTRAVAGINAL DEVICES AND METHOD | |
| NO20083780L (no) | Topisk sammensetning omfattende en antibakteriell substans | |
| BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
| DK2012763T3 (da) | Farmaceutisk kombination omfattende 3-(3-dimethylamono-1-ethyl-2-methyl-propyl) phenol og et NSAID | |
| DK2058317T3 (da) | Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens | |
| CL2013000713A1 (es) | Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial. | |
| DK2012764T3 (da) | Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol | |
| ITFI20050028A1 (it) | Dispositivo, catetere e metodo per il trattamento curativo delle vene varicose | |
| EP2512458A4 (en) | SYSTEM FOR DELIVERING A TOPIC ACTIVE MEDICINE OF LOW TOXICITY | |
| CY1115516T1 (el) | Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα | |
| DK1879654T3 (da) | Farmaceutisk kombination af et afsvampningsmiddel og en aktiv substans, som navnlig er eugenol og carvacrol | |
| ATE510594T1 (de) | Hustenpräparat | |
| ITFI20050239A1 (it) | Idrossammati come inibitori dell'istone deacetilasi e formulazioni farmaceutiche che li contegono | |
| CL2012000801A1 (es) | Composición farmacéutica en solución acuosa que comprende olopatadina y un compuesto derivado de quinolina sustituida, inhibidor de pde4; y uso para el tratamiento de una condición alérgica o inflamatoria del ojo, la nariz o la piel. | |
| EP2351748A4 (en) | ISOCHINOLINE DERIVATIVES AND THESE PDE INHIBITORS CONTAINING ACTIVE SUBSTANCE | |
| ATE511837T1 (de) | Wässrige arzneimittelformulierung von 4-ä((4- carboxybutyl)-ä2-ä(4-phenethyl-benzyl)oxyü- phenethylüamino)methylübenzoesäure | |
| PE20030721A1 (es) | Sales de 4-feniltetrahidroisoquinolinio sustituidas, procedimiento para su preparacion, su uso como medicamentos y medicamento que las contiene |